RxDoctor Payments Data

Girolamo Arpino, DO

Internal Medicine · Peoria, AZNPI 1578710265

Payments from drug & device makers

$7,532in general payments, 2019–2025

Across 390 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$564
  • Harmony Biosciences LLC$552
  • GSK$542
  • Novo Nordisk$514
  • Lilly USA, LLC$505
  • Indivior Inc.$457
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,20596%
  • Education$3274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,532 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$418,533
Medicare patients
437
Services billed
6,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$293,227
FarxigaDapagliflozin Propanediol160$210,446
JardianceEmpagliflozin107$132,175
EliquisApixaban78$103,490
TrulicityDulaglutide55$87,540
JanuviaSitagliptin Phosphate52$73,300
MounjaroTirzepatide56$70,108
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$55,525
XareltoRivaroxaban37$53,540
ProliaDenosumab30$53,045
TradjentaLinagliptin15$23,515
LinzessLinaclotide23$21,363
Humalog Kwikpen U-200Insulin Lispro11$17,285
Tresiba Flextouch U-100Insulin Degludec27$17,258
MyrbetriqMirabegron17$17,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$514$310,351180 claims
AstraZenecaFarxiga, Symbicort$564$226,986189 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$70$170,126142 claims
Lilly USA, LLCTrulicity, Mounjaro$505$157,648111 claims
PfizerEliquis$346$103,49078 claims
MerckJanuvia$21$73,30052 claims
GSKTrelegy Ellipta$542$55,52545 claims
Johnson & JohnsonXarelto$355$53,54037 claims
AmgenProlia$347$53,04530 claims
AbbVieLinzess$350$21,36323 claims
Astellas Pharma US IncMyrbetriq$145$17,15917 claims
NovartisEntresto$59$13,98114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →